As I understand the situation, antibiotic resistance isn't a generally useful adaptation - bacteria tend to lose it "in the wild". So prevalence of antibiotic resistant bacteria, in non human-to-human born diseases like Staph infections, is a somewhat direct result of maintaining a long term, antibiotic filled environment.
Antibiotics have changed the way we live, but the price of that change is that we have to invest in the arms race. We invest in all the other arms races, so why not this one?
Not necessarily a decisive pressure however. For bacteria which primarily "prey" on human beings this would be true. For bacteria which are primarily endemic to the environment, the loss of fitness involved in antibiotic vulnerability is something of a drop in the bucket. Remember this resistance has a cost in physiological adaptation too. These bacteria, like Staph, that might be "happy" to subside to resisting the common chemicals in a barnyard - unless we human produce an environment where tolerating antibiotic gives the organism a natural bridge to spread through - gigantic hospitals with filled with humans pumped with antibiotics or huge feed lots filled with similarly pumped animals "come to mind".
The Russians were particularly interested in this sort of thing during the latter part of the Cold War, as I'm sure the West was, and still is. They were looking at enhancing the immune system as an alternative to antibiotics or vaccines for agents that could not necessarily be fought with antibiotics or vaccines (i.e. biological terrorism). They also looked at using immune response as a bioterror target (e.g. something like the reaction to TGN1412 but using a transmissible bioagent instead of a non-biological agent.) They were keenly aware that the two problems were linked.
Obviously, immune response is bad at all times when there's no active threatening infection to fight, but needs to be maximized at least along certain paths when there's a threatening infection. That was a difficult problem with 1980's technology. I'm optimistic that it's not quite so intractable a problem, at least in cases of common bacterial infections typically treated with antibiotics today. More narrowly targeted immune system boosting seems plausible now that there's a somewhat better understanding of immune system interactions...
Note that one possible flip side of this is auto-immune diseases.
"immune response is bad at all times when there's no active threatening infection to fight"
I don't think that's at all true. Our immune systems tend to work wonderfully most of the time given that we're constantly bathed in potentially pathogenic bacteria. In this discussion scythe says of "the ESKAPE pathogens, which are the primary superbugs" that "in every case except S aureus, infection is basically unheard of when an individual has a functioning immune system; they are all opportunistic pathogens". I take that to mean that for a lot people, temporary immune system dysfunction, e.g. due to other insults to the body, are a big factor.
I noticed on Wikipedia that one of the ESKAPE bacteria, Acinetobacter baumannii (http://en.wikipedia.org/wiki/Acinetobacter_baumannii), "Colloquially, A. baumannii is referred to as 'Iraqibacter' due to its seemingly sudden emergence in military treatment facilities during the Iraq War. It has continued to be an issue for veterans and soldiers who serve in Iraq and Afghanistan. Multidrug resistant (MDR) A. baumannii has spread to civilian hospitals in part due to the transport of infected soldiers through multiple medical facilities."
That I assume is largely due to gross trauma (and lots more soldiers surviving because of much better body armor (even helps in non-comat accidents I've read) and ever better treatment) ... and e.g. car crashes in the US tell us we're not soon going to be rid of that problem....
I should have said wherever rather than at all times when. I don't try to discuss this a lot so I guess I'm not as precise at organizing my thoughts as I'd like to be. Thanks. Yeah, "superbugs" are disproportionately at hospitals, and garden variety bacterial species; they cause problems because patients tend to have wounds or compromised immune systems, and because the frequency of antibiotic use at hospitals encourages thriving populations of resistant strains.
Especially if we can find ways sufficiently weighted towards bacteria. The major thing that saves us with them is that their significant low level differences from eukaryotic cells, e.g. those smaller and different ribosomes that provide a handy target for various antibiotic families (they're the organelles that synthesize proteins). Or their plant style cell walls.
(I stopped paying attention to the details of immune system in the late '70s when I noted how fast we were learning about it, i.e. for me it's something to learn/review "on demand", so I can't make any really specific suggestions as to what to do or judge the feasibility.)
Another promising research avenue is bacteriophages. I don't know why it's being pursued more in the former Soviet Union than it is in the West. I suppose even with targeted bacteriophages there's some risk that they could mutate and start targeting beneficial bacteria, which would be a problem.
A cute CS-inspired theoretical approach would be to throw variable layers at the problem. With genetic engineering, create bacteria that function as a supplemental immune system, but in a very narrow way; the bacteria would, possibly in collaboration with the host immune system, generate specific bacteriophages for any pathogenic bacteria they come into contact with. Obviously it wouldn't work against pathogenic viruses, but other than the (perhaps impossible) difficulty of having a cell able to generate novel bacteriophages, it doesn't seem so outlandish. If we get to the point where we can write code for a wide variety of biological activity and get it translated into DNA, then such a bacteriophage-generating bacterium might be possible.
I realize there are pathologies imaginable with any possible solution. The question is how likely is it that natural or engineered pathogens will target whatever new targets are available. Bacteriophage-generating bacteria could be hijacked by viruses, mutated by gene transfer with harmful bacteria to do bad things, or even give their bacteriophage-generating properties to pathological bacteria which might then gain mutations to generate human-targeting viruses... wouldn't that be fun.
Hospital acquired infection is a significant cause of death.
> In the United States, the Centers for Disease Control and Prevention estimated roughly 1.7 million hospital-associated infections, from all types of microorganisms, including bacteria, combined, cause or contribute to 99,000 deaths each year.
> In Europe, where hospital surveys have been conducted, the category of Gram-negative infections are estimated to account for two-thirds of the 25,000 deaths each year.
(http://en.wikipedia.org/wiki/Hospital-acquired_infection)
These are just nosocomial (hospital acquired) and not necessarily antibiotic resistant.
Can I reach you by email?
Certain honeys -- and not particularly the more expensive ones -- are much more antibacterial in this regard than others.
Speaking more generally, there is limited interest from big pharma in the use of natural or herbal products because they will have to spend a ton of money on clinical trials to prove effectiveness, but they won't get the patent protection necessary to recoup the cost of R&D, like they would with synthetic drugs.
(At least that's the way it was when I was still in the field.)
At the VERY least I urge you to design novel experiments and post them publicly.
I realize that not everyone can be a biochemist and do antibiotics research, but we've reached a place where our most technologically savvy people are frittering their talents on food delivery services and cat videos. I have an advanced degree in biochemistry, and it's still basically impossible to get work doing antibiotics development. There's no money in it. I work on websites, because that's where I need to be to earn a living. If I could get venture capital to do speculative work developing new classes of antibiotics, I'd do that in a heartbeat.
What's the point? I don't really know. Rome is burning, I guess. Bring on the bread and the circuses.
(Postscript: $200M is considered a big initiative in this space. We spend BILLIONS on niche diseases: http://online.wsj.com/article/SB1000142412788732397500457849...)